Screening Compounds Targeting CBP20 and CBP80 for HIV Latency Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, particularly HIV, face challenges such as drug resistance, side effects, and the need for long-term administration, with existing therapies failing to cure the infection and allowing viral load rebound due to latent virus reservoirs.
Innovation Solution
A method for screening compounds that interact with or promote the interaction between Cap-Binding Proteins CBP20 and CBP80, specifically targeting the Cap-Binding Complex to inhibit viral replication and reduce viral load, while maintaining minimal cytotoxicity and avoiding resistance development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ART drugs are used to control HIV infection, then viral load is reduced during treatment, but viral load rebounds after treatment discontinuation due to virus latency
Solution Approach 1:
The patent screens compounds that can prevent viral latency establishment in the first place, rather than merely suppressing active replication. By targeting the latent reservoir formation process, the invention aims to eliminate the root cause of rebound before it occurs, enabling potential functional cure strategies.
Solution Approach 2:
The invention uses cellular and molecular markers (such as integration sites, epigenetic markers, and transcriptional intermediates) as mediators to detect and target latent virus reservoirs. These intermediaries provide measurable indicators of latency status, allowing for screening of compounds that can disrupt the latent reservoir maintenance mechanisms.
2Reliability
If HAART combination therapy is administered long-term, then disease progression is controlled, but drug resistance and side effects develop
Solution Approach 1:
The patent extracts and targets specific mechanisms unique to viral latency and reservoir maintenance, rather than broadly suppressing all viral replication. By focusing on latency-specific processes (such as integration site selection, epigenetic silencing, and transcriptional repression), the invention seeks to eliminate latent reservoirs without requiring continuous high-dose combination therapy, thereby reducing resistance pressure and side effects.
Solution Approach 2:
The invention screens compounds that can alter key parameters of latency maintenance, such as chromatin accessibility, transcription factor binding affinity, and integration site distribution. By changing these fundamental parameters that govern latent reservoir persistence, the approach aims to achieve durable control with different mechanisms than current replication inhibitors, potentially overcoming resistance issues.
3Reliability
If indole derivatives are used to interfere with splicing enhancer activity, then viral protein production is suppressed, but cellular toxicity increases
Solution Approach 1:
The patent screens compounds that exhibit selective toxicity toward viral-infected cells or specifically target viral splicing mechanisms while sparing cellular processes. By achieving local specificity in the action mechanism (targeting viral SRSF1 interactions versus cellular splicing factors), the invention aims to maintain antiviral efficacy while reducing off-target cellular damage.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).